2024
In vitro efficacy of next-generation dihydrotriazines and biguanides against babesiosis and malaria parasites
Vydyam P, Chand M, Gihaz S, Renard I, Heffernan G, Jacobus L, Jacobus D, Saionz K, Shah R, Shieh H, Terpinski J, Zhao W, Cornillot E, Mamoun C. In vitro efficacy of next-generation dihydrotriazines and biguanides against babesiosis and malaria parasites. Antimicrobial Agents And Chemotherapy 2024, 68: e00423-24. PMID: 39136469, PMCID: PMC11373198, DOI: 10.1128/aac.00423-24.Peer-Reviewed Original ResearchTherapeutic indexPlasmodium falciparum</i>Effective therapeutic strategyCausative agent of babesiosisIn vitro efficacyAntiparasitic drugsProtozoan parasitesMalaria parasitesIntraerythrocytic protozoan parasiteTherapeutic strategiesFolate pathwayBroad-spectrum antiparasitic drugStrain HB3Babesia divergensMalariaBabesia duncaniAnimal healthAntifolatesDrugWidespread resistanceCausative agentBiguanideBabesiaBabesiosisBiosynthesis of purinesA set of diagnostic tests for detection of active Babesia duncani infection
Chand M, Vydyam P, Pal A, Thekkiniath J, Darif D, Li Z, Choi J, Magni R, Luchini A, Tonnetti L, Horn E, Tufts D, Ben Mamoun C. A set of diagnostic tests for detection of active Babesia duncani infection. International Journal Of Infectious Diseases 2024, 147: 107178. PMID: 39025200, PMCID: PMC11914778, DOI: 10.1016/j.ijid.2024.107178.Peer-Reviewed Original ResearchB. microtiB. duncaniBlood samplesLife-threatening infectionsAntigen capture assayTick-borne diseasesFatal tick-borne diseaseP. falciparumBabesia genusScreening of blood samplesBabesia speciesB. divergensActive infectionAccurate diagnosisEffective disease managementPoint-of-care testingDiagnostic testsReservoir hostsBabesiaInfectionHuman babesiosisIntraerythrocytic parasitesImmunodominant antigensMolecular assaysCapture assay
2022
Epidemiology of Hospitalized Patients with Babesiosis, United States, 2010–2016 - Volume 28, Number 2—February 2022 - Emerging Infectious Diseases journal - CDC
Bloch EM, Day JR, Krause PJ, Kjemtrup A, O’Brien S, Tobian AAR, Goel R. Epidemiology of Hospitalized Patients with Babesiosis, United States, 2010–2016 - Volume 28, Number 2—February 2022 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2022, 28: 354-362. PMID: 35076004, PMCID: PMC8798708, DOI: 10.3201/eid2802.210213.Peer-Reviewed Original ResearchConceptsNational Inpatient Sample databaseInfectious Diseases journal - CDCAnalysis of hospitalizationsHospitalized patientsAdvanced ageMortality rateHospitalizationSample databaseObservation periodEpidemiologyHigher severityPatientsBabesiosisDiagnosisUnited StatesReporting dataBabesiaAdmissionIllnessIncidenceDiseaseSeverity
2021
The Global Emergence of Human Babesiosis
Kumar A, O’Bryan J, Krause PJ. The Global Emergence of Human Babesiosis. Pathogens 2021, 10: 1447. PMID: 34832603, PMCID: PMC8623124, DOI: 10.3390/pathogens10111447.Peer-Reviewed Original ResearchHuman babesiosisPrimary clinical characteristicsEndemic diseaseGlobal health burdenHard-bodied ticksMode of transmissionFulminant casesTick-borne diseaseClinical characteristicsBlood transfusionDisease locationHealth burdenOrgan transplantationEpidemiologic toolIntraerythrocytic protozoaDiseaseBabesiosisInfectionLike agentsGlobal emergenceHuman pathogensUnited StatesBabesiaWide spectrumPredominant species
1981
Raccoon babesiosis in Connecticut, USA: Babesia lotori sp. n.
Anderson J, Magnarelli L, Sulzer A. Raccoon babesiosis in Connecticut, USA: Babesia lotori sp. n. Journal Of Parasitology 1981, 67: 417-25. PMID: 7021788, DOI: 10.2307/3280566.Peer-Reviewed Original ResearchConceptsYoung raccoonsInfected raccoonsIndirect fluorescent antibody testSpecies of BabesiaFluorescent antibody testAntibody titersIxodes texanusSeropositive raccoonsBabesiaLow infection rateProcyon lotorRaccoonsAntibody testInfected bloodInfection rateParasitemiaBabesiosisTicksIxodesTitersProcyonSpeciesSp.
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply